

Press release

EQL PHARMA

Lund 27 April 2026

EQL Pharma AB

Reg. No. 556713-3425

EQL Pharma in process of recruiting new Chief Supply Chain Officer (CSCO)

EQL Pharma is recruiting a new CSCO with a clear CMO/CDMO background. This means that the current Chief Supply Chain Officer (CSCO) Magnus Erreth will leave his position. Magnus has been active in EQL Pharma since 2024 and will remain in his role until mid June 2026 and ensure a stable handover.

- We would like to thank Magnus for his efforts during his tenure with EQL Pharma, especially given the challenging supply environment.

"I would like to thank Magnus for his efforts with EQL. We wish him all the best for the future," says Axel Schörling, CEO of EQL Pharma.

The process to recruit a new CSCO has been initiated, and the Company will provide more information as soon as possible.

For additional information, please contact:

Axel Schörling

President and CEO EQL Pharma AB (publ)

Phone: +46 (0) 76 317 90 60

E-Mail: axel.schorling@eqlpharma.com

Website: www.eqlpharma.com

EQL Pharma AB briefly

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 47 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2025 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.